A multicenter Phase II study of Epirubicin (E) with low-dose Herceptin (LD-H) as a first line treatment in HER-2 overexpressing metastatic breast cancer (MBC): Preliminary results

被引：0
|
作者：
De Tursi, M.
Carella, C.
Ricevuto, E.
Marchetti, P.
Gennari, A.
Orlandini, C.
Frassoldati, A.
Conte, P.
Iacobelli, S.
机构：
[1] Univ G dAnnunzio, Dept Oncol & Neurosci, Chieti, Italy
[2] Univ Aquila, Dept Oncol, I-67100 Laquila, Italy
[3] Univ Pisa, Dept Oncol, I-56100 Pisa, Italy
[4] Univ Modena, Dept Oncol, I-41100 Modena, Italy
来源：
EJC SUPPLEMENTS | 2005年 / 3卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：116 / 116
页数：1
相关论文
共 50 条
  • [1] A multicenter phase II study of epirubicin (E) with low-dose herceptin (LD-H) as a first-line treatment in HER2 overexpressing metastatic breast cancer (MBC)
    De Tursi, M.
    Carella, C.
    Ricevuto, E.
    Gennari, A.
    Orlandini, C.
    Frassoldati, A.
    Conte, P. F.
    Iacobelli, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [2] A multicenter phase II study of Epirubicin with low-dose Herceptin as a first line treatment in HER-2 overexpressing metastatic breast cancer
    De Tursi, M.
    Carella, C.
    Ricevuto, E.
    Gennari, A.
    Orlandini, C.
    Frassoldati, A.
    Conte, P. F.
    Iacobelli, S.
    BREAST, 2007, 16 : S41 - S41
  • [3] A multicenter phase II study of epirubicin with low-dose trastuzumab as a first line treatment in Her-2 overexpressing metastatic breast cancer: preliminary results
    不详
    EJC SUPPLEMENTS, 2006, 4 (02): : 165 - 165
  • [4] Multinational phase II study of navelbine (N) and herceptin (H) as first-line therapy for HER2-overexpressing metastatic breast cancer (HER2+MBC).
    Chan, A
    Untch, M
    Petruzelka, L
    Martin, M
    Porta, VG
    Gil, M
    Kellokumpu-Lehtinen, P
    BREAST CANCER RESEARCH AND TREATMENT, 2002, 76 : S112 - S112
  • [5] Multicenter phase II study of trastuzumab in combination with epirubicin and docetaxel as first-line treatment for HER2-overexpressing metastatic breast cancer
    M. Venturini
    C. Bighin
    S. Monfardini
    F. Cappuzzo
    N. Olmeo
    A. Durando
    F. Puglisi
    O. Nicoletto
    A. Lambiase
    L. Del Mastro
    Breast Cancer Research and Treatment, 2006, 95 : 45 - 53
  • [6] Multicenter phase II study of trastuzumab in combination with epirubicin and docetaxel as first-line treatment for HER2-overexpressing metastatic breast cancer
    Venturini, M
    Bighin, C
    Monfardini, S
    Cappuzzo, F
    Olmeo, N
    Durando, A
    Puglisi, F
    Nicoletto, O
    Lambiase, A
    Del Mastro, L
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 95 (01) : 45 - 53
  • [7] Docetaxel with epirubicin as first line chemotherapy in metastatic breast cancer (MBC).: Final results of a Phase II study
    Morales, S
    Lorenzo, A
    Ramos, M
    Ballesteros, P
    Méndez, M
    Almanza, C
    Moreno-Nogueira, J
    Casal, J
    Castellanos, J
    Lizón, J
    EUROPEAN JOURNAL OF CANCER, 2002, 38 : S68 - S68
  • [8] Preliminary results of a phase II study of epirubicin and paclitaxel as first-line treatment in patients with metastatic breast cancer
    Luck, HJ
    Thomssen, C
    duBois, A
    Lisboa, BW
    Untch, M
    Kuhnle, H
    Janicke, F
    Meerpohl, HG
    Lindner, C
    Kcnecny, G
    Hecker, D
    Diergarten, K
    SEMINARS IN ONCOLOGY, 1997, 24 (01) : S13 - S16
  • [9] FIRST LINE BE-WEEKLY REGIMEN WITH DOCETAXEL AND GEMCITABINE IN HER-2 NEGATIVE AND ANTRACYCLINE-PRETREATED METASTATIC BREAST CANCER (MBC) PATIENTS: PRELIMINARY RESULTS OF A MULTICENTER PHASE II TRIAL
    Murialdo, R.
    Bertolotti, F.
    Tixi, L.
    Boy, D.
    Martini, M. C.
    Pastorino, G.
    Sogno, G.
    Vaira, F.
    Bergaglio, M.
    Mencoboni, M.
    Simoni, C.
    Parodi, M.
    Canobbio, L.
    Folco, U.
    Ballestrero, A.
    Brema, F.
    ANNALS OF ONCOLOGY, 2009, 20
  • [10] A multinational phase II study of Navelbine (N) and Herceptin (H) as first-line therapy for patients with HER2-positive metastatic breast cancer (HER2+MBC)
    Untch, M.
    Kahlert, S.
    Petruzelka, L.
    Martin, M.
    Guillem-Porta, V.
    Gil, M.
    Kellokumpu-Lehtinen, P.
    Aubert, D.
    Gasmi, J.
    Chan, A.
    EJC SUPPLEMENTS, 2004, 2 (03): : 127 - 127
12345